March 15, 2026 a 08:38 am
KVUE: Analysts Ratings - Kenvue Inc.
The recent analyst ratings of Kenvue Inc. show a stable trend with a dominance of 'Hold' recommendations. The company, being a subsidiary of Johnson & Johnson, operates across various consumer health markets. With a consistent performance across its segments, the stock remains a cautious interest for potential investors, as indicated by the overwhelming hold sentiment among analysts.
Historical Stock Grades
| Recommendation | Count | Visual Score |
|---|---|---|
| Strong Buy | 1 | |
| Buy | 1 | |
| Hold | 10 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
- The 'Hold' rating consistently rises, indicating a cautious market stance.
- There was a gradual decline in 'Strong Buy' and 'Buy' recommendations over the past year.
- Overall analyst activity shows a decrease, reflecting either consensus or uncertainty.
Percentage Trends
- The 'Hold' recommendations constitute about 80% of total ratings, showing market caution.
- There is a significant reduction in 'Buy' and 'Strong Buy' ratings, dropping from 2025 levels.
- Analysts display increased reticence, suggesting potential market stability concerns or divided outlooks.
Latest Analyst Recommendations
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-03-06 | Equal Weight | Equal Weight | Barclays |
| 2026-02-18 | Neutral | Neutral | Citigroup |
| 2026-02-18 | Neutral | Neutral | UBS |
| 2026-02-18 | Hold | Hold | Canaccord Genuity |
| 2026-01-30 | Hold | Buy | Jefferies |
Analyst Recommendations with Change of Opinion
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-01-30 | Hold | Buy | Jefferies |
| 2025-10-29 | Hold | Buy | Canaccord Genuity |
| 2025-09-26 | Buy | Neutral | Rothschild & Co |
| 2025-01-06 | Overweight | Neutral | Piper Sandler |
| 2024-12-12 | Hold | Buy | Deutsche Bank |
Interpretation
The prevailing 'Hold' recommendations suggest a balanced view of Kenvue Inc., marked by cautious optimism and a restrained approach. Analysts seem to express uncertainty regarding the immediate prospects, potentially due to macroeconomic factors or shifts in consumer health trends. Despite the minor downgrades, the recommendations are fairly consistent, indicating a lack of consensus on bullish advances. Overall, the analyst sentiment appears stable but leans towards caution rather than aggressive investment strategies.
Conclusion
Kenvue Inc., as a subsidiary of Johnson & Johnson, finds itself in a robust yet cautiously observed market position. The prevailing 'Hold' sentiment reflects stability rather than aggressive growth prospects. This sentiment, coupled with recent downgrades, suggests that while there is confidence in the company’s underlying value, market dynamics are being carefully observed. Opportunities may exist through strategic segments like Self Care, but caution remains advisable amid a predominantly stable yet tentative analyst outlook.